This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Progenics Pharmaceuticals' Data From A Phase 1 Study Of PSMA ADC Presented At ASCO 2013

TARRYTOWN, N.Y., June 1, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today reported findings from the phase 1 clinical trial in prostate cancer patients of its PSMA ADC compound at the 49 th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Two additional abstracts related to PSMA ADC also were selected for publication in the ASCO Annual Meeting Proceedings.

Daniel Petrylak, M.D., Director of the Prostate Cancer Program/Genitourinary Cancer Program and Co-Director of the Signal Transduction Program at Yale University Medical Center, and an investigator in clinical trials of PSMA ADC, presented "Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC): A Phase I Trial in Metastatic Castration-Resistant Prostate Cancer Previously Treated with a Taxane" in the Genitourinary Cancer Poster Discussion Session.

"Phase 1 results for PSMA ADC, together with the additional data published in the Proceedings by my colleagues, reinforce our ongoing interest in PSMA as a compelling target in treating prostate cancer," said Robert J. Israel, M.D., Progenics' senior vice president of medical affairs and clinical research. "The phase 2 trial of PSMA ADC is on track to meet our goal of completing enrollment by the end of this year, with more than half the number of planned patients currently in the trial."

Additional abstracts published in the ASCO 2013 Annual Meeting Proceedings are:

#e16047: Correlation of PSMA ADC Exposure with Reduction in Tumor Growth Rate Determined Using Serial PSA Measurements from a Phase I Clinical Trial

#e16007: Antiandrogen Modulation of Prostate-Specific Membrane Antigen (PSMA): Dynamics and Synergy with PSMA-Targeted Therapy

Progenics' exhibit booth, #22054, presents details of the company's expanded oncology pipeline including the PSMA-targeted imaging compound 1404, a development stage radio-labeled small molecule designed to visualize cancer.

About the PSMA ADC Phase 1 Study Design

The phase 1, open-label, dose-escalation clinical trial was conducted in men with hormone-refractory prostate cancer that had progressed despite prior treatment with taxane-based chemotherapy regimens. In addition to assessing PSMA ADC's safety and tolerability, the study included evaluations of pharmacodynamics, changes in tumor burden, and changes in PSA and CTC values compared to baseline. PSA is a secreted protein that is distinct from PSMA.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs